Slide 1: Q2 CellaVision Interim Report January-June 2024
Q2 CellaVision Interim Report January-June 2024 Solid Quarter and Growth in APAC Organic sales growth: Q2, 2024: 10% (-15) EBITDA margin: Q2, 2024: 32% (33) January 1 – June 30, 2024 Net sales increased by 11% (-8) to SEK 188 m (170). Sales increased organically by 10% (-15), currency effect 1% (7).
Slide 2: CEO's Comment
CEO’s Comment Second quarter marked a period of stability Integrated Health Networks (IHNs) in fully Following the Strategic Alliance Agreement for CellaVision. Growth in APAC was broad digitalizing hematology laboratories. Our small entered in the previous quarter, this quarter with most markets de
Slide 3: Sales, Earning and Investments
Sales, Earning and Investments Net Sales and Currency Effects development expenses, inventory adjustments as well as currency regulatory requirements. Research and development costs have Net sales for the Group’s second quarter increased by 11 percent to effects. The lower gross margin during the qu
Slide 4: Investments and Cash Flow
Investments CellaVision continuously capitalizes expenses for product development. Capitalized development expenses amounted to SEK 16 m (14) during the quarter. The quarter’s total research and development expenses, before capitalization, amounted to SEK 36 m (35). For the six-month period capitali
Slide 5: Development in the Geographical Markets
Development in the Geographical Markets Americas: SEK 67 m (81) EMEA: SEK 83 m (76) APAC: SEK 37 m (13) In the Americas, sales decreased by 17 percent to SEK 67 m In EMEA, sales increased by 10 percent to SEK 83 m (76) in While sales generally fluctuate in APAC, signs of positive (81) compared to th
Slide 6: Research and Development
Research and Development Improving healthcare through continuous The development of Fourier Ptychographic innovation is a fundamental ambition Microscopy (FPM) is progressing, and patent of CellaVision. The company devotes applications have been filed for several considerable resources to research n
Slide 7: Declaration by the Board of Directors and President/CEO
Declaration by the Board of Directors and President/CEO The Board of Directors through the President/Chief Executive Officer certify that the interim report provides a true and fair view of the parent company´s and the Group´s business, financial position, performance and describes material risks an
Slide 8: Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Group Amounts in ' 000 SEK Note Apr-Jun 2024 Apr-Jun 2023 Jan-Jun 2024 Jan-Jun 2023 Jan-Dec 2023 Net sales 4 187,793 169,668 357,873 308,764 677,292 Cost of goods sold -63,243 -50,834 -121,257 -93,070 -214,251 Gross prof
Slide 9: Per Share Data and Quarterly Earnings Trend
Per Share Data Per share data Apr-Jun 2024 Apr-Jun 2023 Jan-Jun 2024 Jan-Jun 2023 Jan-Dec 2023 Earnings per share, before and after dilution, SEK */ 1.62 1.46 2.88 2.26 5.46 Equity per share, SEK 31.00 27.66 31.00 27.66 30.04 Number of shares outstanding 23,851,547 23,851,547 23,851,547 23,851,547 2
Slide 10: Balance Sheet in Summary, Group
Balance Sheet in Summary, Group Amounts in ' 000 SEK Note 06/30/2024 06/30/2023 03/31/2024 12/31/2023 Assets Intangible assets 5 459,676 429,496 451,295 433,223 Tangible assets 6 122,580 125,537 126,420 125,502 Financial assets 7 3,883 4,993 3,942 4,396 Inventory 118,614 156,932 122,251 126,038 Trad
Slide 11: Cash Flow Statement in Summary, Group
Cash Flow Statement in Summary, Group Amounts in ' 000 SEK Apr-Jun 2024 Apr-Jun 2023 Jan-Jun 2024 Jan-Jun 2023 Jan-Dec 2023 Result before taxes 48,211 44,338 86,455 68,697 164,222 Adjustment for items not included in cash flow 14,316 15,035 31,077 25,135 49,382 Income tax paid -7,837 -6,952 -13,081
Slide 12: Income Statement in Summary, Parent Company
Income Statement in Summary and Consolidated Statement of Comprehensive Income, Parent Company Amounts in ' 000 SEK Apr-Jun 2024 Apr-Jun 2023 Jan-Jun 2024 Jan-Jun 2023 Jan-Dec 2023 Net sales 146,350 129,735 273,970 232,789 523,473 Cost of goods sold -37,427 -27,934 -70,874 -47,929 -118,814 Gross pro
Slide 13: Balance Sheet in Summary, Parent Company
Balance Sheet in Summary, Parent Company Amounts in ' 000 SEK 06/30/2024 06/30/2023 03/31/2024 12/31/2023 Assets Intangible assets 28,439 31,430 29,187 29,935 Tangible assets 5,566 5,918 5,385 5,770 Deferred tax assets 496 733 496 496 Long term receivables from group companies 34,079 32,722 35,728 3
Slide 14: Notes
Notes NOTE 1. ACCOUNTING POLICIES NOTE 3. RISKS AND UNCERTAINTIES The Group applies IFRS Accounting Standards, as adopted by the EU. This interim report has CellaVision is exposed to several risks, which may impact the Group’s development to a greater been prepared in accordance with IAS 34 Interim
Slide 15: Notes, Cont'd
Notes, Cont’d NOTE 5. INTANGIBLE ASSETS NOTE 7. FINANCIAL ASSETS AND LIABILITIES Amounts in ' 000 SEK 06/30/2024 06/30/2023 The disclosed value of financial assets, trade receivables, other receivables, cash and bank, Capitalised expenditure for development 237,625 187,453 trade payables, and other
Slide 16: Reconciliation Tables KPIs, Non-IFRS Measures
Reconciliation Tables KPIs, Non-IFRS Measures The company presents certain financial measures in the interim report which are not defined according to IFRS. The to IFRS. Definitions of measures which are not defined EBITDA. Overall financial performance before interest, financial metrics are used by
Slide 17: Questions Concerning the Report
Questions Concerning the Report Publication This information constitutes information that CellaVision AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication at 7:20 a.m. CEST on July 19, 202
Slide 18: This is CellaVision
This is CellaVision About Us Our Strategic Ambition: The power of focus Mission CellaVision is an innovative, global medical technology company Our strategic ambition is to digitalize and improve microscopy Our mission is to advance laboratory that develops and sells its own leading solutions for ro